Update shared on 30 Oct 2025
Fair value Decreased 8.11%Analysts have adjusted their price target for Akebia Therapeutics from $7.40 to $6.80. They cite slight shifts in projected valuation metrics and underlying financial assumptions.
What's in the News
- Akebia Therapeutics will not initiate the VALOR clinical trial for vadadustat in late-stage chronic kidney disease (CKD) patients not on dialysis after failing to reach alignment with the FDA on trial design and scope (Key Developments).
- The company determined that regulatory alignment for the VALOR trial would require a much larger patient population, resulting in increased time and cost (Key Developments).
- VAFSEO is not recommended for patients with anemia due to CKD who are not on dialysis because safety has not been established and increased risks were observed in clinical trials (Key Developments).
- Vafseo (vadadustat) is now broadly available for anemia due to CKD in dialysis patients through Innovative Renal Care's network of over 230 clinics in 28 states and Washington, D.C. (Key Developments).
- Akebia has initiated the VOCAL post-marketing study to assess the efficacy and safety of three-time weekly vadadustat dosing versus standard care in hemodialysis patients (Key Developments).
Valuation Changes
- Consensus Analyst Price Target has decreased from $7.40 to $6.80, reflecting a modest downward revision.
- Discount Rate has increased slightly from 7.01% to 7.43%.
- Revenue Growth projection is nearly unchanged, inching up from 20.52% to 20.53%.
- Net Profit Margin expectation has risen from 20.08% to 20.62%.
- Future P/E ratio estimate has fallen from 41.02x to 37.13x. This indicates a lower expected valuation relative to earnings.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.